Clinical ResearchMyocardial InfarctionPlasma N-Terminal B-Type Natriuretic Peptide as an Indicator of Long-Term Survival After Acute Myocardial Infarction: Comparison With Plasma Midregional Pro-Atrial Natriuretic Peptide: The LAMP (Leicester Acute Myocardial Infarction Peptide) Study
Myocardial Infarction
Under an Elsevier user license
open archive
Abbreviations and Acronyms
AMI
acute myocardial infarction
ANP
atrial natriuretic peptide
AUC
area under the curve(s)
BNP
B-type natriuretic peptide
CI
confidence interval
CV
coefficient of variation
eGFR
estimated glomerular filtration rate
HF
heart failure
HR
hazard ratio
MI
myocardial infarction
MR-proANP
midregional proatrial natriuretic peptide
NSTEMI
non–ST-segment elevation myocardial infarction
NT-proBNP
N-terminal pro-B-type natriuretic peptide
STEMI
ST-segment elevation myocardial infarction
Cited by (0)
Dr. Khan was supported by a Junior Fellowship from the British Heart Foundation (FS/03/028/15486). Dr. Ng has submitted patents on behalf of the University of Leicester on biomarkers of cardiac disease. Dr. Bergmann holds ownership in BRAHMS AG, patent rights to the midregional proatrial natriuretic peptide (MR-proANP) assay, and is a member of the board of directors of BRAHMS AG. Dr. Struck holds patent rights to the MR-proANP assay and is an employee of BRAHMS AG. Dr. Morgenthaler is an employee of BRAHMS AG. All authors had full access to the data and take responsibility for its integrity and the accuracy of the analysis. All authors have read and agree to the article as written.
Copyright © 2008 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.